🌍 Society & Frontier risk-on · 1–3 years
A what‑if from the future

What if China-pharma PD-1/ADC innovation reshapes oncology competition?

Low-cost, high-quality Chinese oncology assets win global licensing and compete on price, pressuring Western pricing while rewarding deal-active partners.

29%
our model probability
over 1–3 years
prediction markets — wisdom of the crowd
loading live odds…
Empirically anchored 29% · 90% range 2–56% · 23 analogues · measured class health 42% in 3 yr · 3% held back for the unknown
how we built this number — every step
Measured class rate — health ≈0.1843/yr → 42% in 3 yr42%
Analyst prior · editorial share 71% of the class30%
Pooled · weight 79%30%
Crowd — no liquid market
Reserve 3% · no extremizing (×1.0)30%
Published29%

The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.

The butterfly cascade

How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.

Resolution timeline — how this probability is moving

Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.

loading the timeline…

What it would mean

If this plays out, it is a risk-on shock. Low-cost, high-quality Chinese oncology assets win global licensing and compete on price, pressuring Western pricing while rewarding deal-active partners. The trigger decomposes into signed root‑shocks — Biotech breakthrough ▲ · Risk appetite ▲ · Trade tension ▲ — which propagate through our causal graph to the markets below.

If it happens — the markets it would move

Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.

MarketClassProjected move
1Solana SOLon Hyperliquid 📈 chartCrypto▲ +0.4%
hist -6.88–+3.66%
2MicroStrategy MSTRon Hyperliquid 📈 chartEquity▲ +0.4%
hist -4.31–+12.0%
3Hyperliquid (HYPE) HYPEon HyperliquidCrypto▲ +0.3%
model prior · unmeasured
4Ether ETHon Hyperliquid 📈 chartCrypto▲ +0.3%
hist -3.48–+2.4%
5Bitcoin BTCon Hyperliquid 📈 chartCrypto▲ +0.2%
hist -2.09–+4.77%
6S&P 500 SPXon Hyperliquid 📈 chartIndex▲ +0.2%
hist +0.07–+0.12%
7Volatility (VIX) VIXon Hyperliquid 📈 chartVol▼ -0.2%
hist -1.3–+2.3%
8Semiconductors SMHon Hyperliquid 📈 chartEquity▼ -0.2%
hist -0.32–+0.68%
9Alibaba BABAon Hyperliquid 📈 chartEquity▼ -0.1%
hist -4.62–+1.19%
10AMD AMDon Hyperliquid 📈 chartEquity▼ -0.2%
hist -0.18–+0.12%
11Broadcom AVGOon Hyperliquid 📈 chartEquity▼ -0.2%
hist -0.8–+1.5%
12Micron MUon Hyperliquid 📈 chartEquity▼ -0.2%
hist -2.02–+0.91%
13TSMC TSMon Hyperliquid 📈 chartEquity▼ -0.2%
hist -0.59–+0.95%
14Marvell MRVLon Hyperliquid 📈 chartEquity▼ -0.2%
hist -1.44–+3.01%

Probable recommendation

If the scenario above plays out, the probable cross‑asset positioning → a scenario‑conditional read, not personalized investment advice
For a common-man portfolio: A typical stock-heavy portfolio should benefit. Stay invested; you can lean modestly into the beneficiaries below.

Historical precedent — what analogous events actually did

Across 23 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.

Wegovy 2021-06 First mRNA COVID-19 vaccine authorized 2020-12 Casgevy — first CRISPR gene-editing medicine approved 2023-12 mRNA pioneers win the Nobel 2023-10 First genetically-modified pig-to-human heart transplant 2022-01 AlphaFold cracks the protein-folding problem 2020-11 He Jiankui announces CRISPR-edited babies 2018-11 Human Genome Project completed 2003-04 China retaliates to Liberation Day: 34% tariffs + rare-earth controls 2025-04 Gold tops $3,000 for the first time amid tariff and rate-cut fears 2025-03 Nikkei 225 record single-day rebound 2024-08 Neuralink implants its first human brain-computer interface 2024-01 LK-99 room-temperature superconductor claim 2023-07 OpenAI releases GPT-4 2023-03 NIF achieves fusion ignition 2022-12 Chinese yuan breaks 7 per dollar; US names China manipulator 2019-08 Mexican peso crash on Trump 2016 win 2016-11 AlphaGo defeats Lee Sedol 2016-03 SpaceX lands an orbital rocket booster 2015-12 2008 global rice crisis: Thai benchmark tops $1,000/ton 2008-04 Soviet August coup attempt against Gorbachev 1991-08 Cuban Missile Crisis 1962-10 Smoot-Hawley clears the US House 1929-05
AssetHistory saysAbnormal (20d · 5d)HitnConfidencevs cascade
BABA BABASHORT-4.0% · 5d -2.2%71%18 0.33✓ matches cascade
SOL SOLSHORT-7.0% · 5d -9.4%71%13 0.30⚠ differs
US dollar DXYSHORT-0.5% · 5d -0.3%67%21 0.29·
Gold XAULONG+0.6% · 5d -0.1% ↺ fades62%20 0.21·
MSTR MSTRLONG+11.0% · 5d -0.6% ↺ fades58%20 0.15✓ matches cascade
SMH SMHLONG+0.7% · 5d +0.6%60%20 0.15⚠ differs
Bitcoin BTCLONG+4.5% · 5d -4.8% ↺ fades58%18 0.13✓ matches cascade
AVGO AVGOLONG+1.6% · 5d -1.2% ↺ fades58%18 0.13⚠ differs
ETH ETHSHORT-3.8% · 5d -8.0%56%15 0.10⚠ differs
10y yield DGS10LONG+4bp · 5d +3bp56%21 0.09·
High-yield credit HYGSHORT-0.0% · 5d -0.3%55%19 0.07·
MRVL MRVLLONG+3.0% · 5d -0.6% ↺ fades54%20 0.06⚠ differs
SPX SPXSHORT+-0.0% · 5d +1.2% ↺ fades40%21 0.00⚠ differs
Volatility VIXLONG+2.4% · 5d -5.1% ↺ fades50%21 0.00⚠ differs

Methodology. Probability and impact are anchored to history and scored against what actually happens — wins and losses, in public, at Reality Check. Crowd odds live from Polymarket & Kalshi. By Vikas Singh, Quantitative Strategist. Updated 2026-07-03.